Search Results - "GUT, R. Z."

Self‐reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (P‐FiQ) study by Witkop, M., Neff, A., Buckner, T. W., Wang, M., Batt, K., Kessler, C. M., Quon, D., Boggio, L., Recht, M., Baumann, K., Gut, R. Z., Cooper, D. L., Kempton, C. L.

“…Introduction Haemophilia is characterized by frequent haemarthrosis, leading to acute/chronic joint pain. Aim To assess self‐reported prevalence, description…”
Get full text

Impact of pain and functional impairment in US adults with haemophilia: Patient‐reported outcomes and musculoskeletal evaluation in the pain, functional impairment and quality of life (P‐FiQ) study by Kempton, C. L., Recht, M., Neff, A., Wang, M., Buckner, T. W., Soni, A., Quon, D., Witkop, M., Boggio, L., Gut, R. Z., Cooper, D. L.

“…Introduction Standardized and disease‐specific patient‐reported outcome (PRO) instruments assessing pain, functional impairment and health‐related quality of…”
Get full text

Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008) by Young, G., Cooper, D. L., Gut, R. Z.

“…Summary Control of bleeding in patients with congenital haemophilia with inhibitors requires use of bypassing agents such as recombinant activated factor VII…”
Get full text

US experience with recombinant factor VIIa for surgery and other invasive procedures in acquired haemophilia: analysis from the Hemostasis and Thrombosis Research Society Registry by Ma, A. D., Kessler, C. M., Al-Mondhiry, H. A. B., Gut, R. Z., Cooper, D. L.

“…Introduction Acquired haemophilia (AH) is a rare disorder caused by autoantibodies against factor VIII. Aim The Hemostasis & Thrombosis Research Society (HTRS)…”
Get full text

Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg−1) rFVIIa doses across clinical trials and registries by Shapiro, A. D., Neufeld, E. J., Blanchette, V., Salaj, P., Gut, R. Z., Cooper, D. L.

“…Summary Recombinant activated factor VII (rFVIIa) is indicated for treatment of bleeding in congenital haemophilia with inhibitors (CHwI) using 90 μg kg−1…”
Get full text

Patient/Caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE) by YOUNG, G., SHAPIRO, A. D., WALSH, C. E., GRUPPO, R. A., GUT, R. Z., COOPER, D. L.

“…Patients with congenital haemophilia with inhibitors experience acute bleeds managed with bypassing agents, such as recombinant FVIIa (rFVIIa). Home‐based…”
Get full text

US experience with recombinant factor VII a for surgery and other invasive procedures in acquired haemophilia: analysis from the Hemostasis and Thrombosis Research Society Registry by Ma, A. D., Kessler, C. M., Al‐Mondhiry, H. A. B., Gut, R. Z., Cooper, D. L.

“…Introduction Acquired haemophilia ( AH ) is a rare disorder caused by autoantibodies against factor VIII . Aim The Hemostasis & Thrombosis Research Society (…”
Get full text

Safety of recombinant activated factor VII ( rFVII a) in patients with congenital haemophilia with inhibitors: overall rFVII a exposure and intervals following high (>240 μg kg −1 ) rFVII a doses across clinical trials and registries by Shapiro, A. D., Neufeld, E. J., Blanchette, V., Salaj, P., Gut, R. Z., Cooper, D. L.

“…Summary Recombinant activated factor VII ( rFVII a) is indicated for treatment of bleeding in congenital haemophilia with inhibitors (CHwI) using 90 μg kg −1…”
Get full text

Assessment of acquired hemophilia patient demographics in the United States: the Hemostasis and Thrombosis Research Society Registry by Kessler, Craig M, Ma, Alice D, Al-Mondhiry, Hamid A.B, Gut, Robert Z, Cooper, David L

“…The Hemostasis and Thrombosis Research Society (HTRS) Registry was used to monitor the postapproval use of recombinant factor VIIa. The objective of this…”
Get full text

A novel supplemental approach to capturing post-marketing safety information on recombinant factor VIIa in acquired hemophilia: the Acquired Hemophilia Surveillance project by Lentz, Steven R, Tandra, Anand, Gut, Robert Z, Cooper, David L

“…Steven R Lentz,1 Anand Tandra,2 Robert Z Gut,3 David L Cooper31Division of Hematology, Oncology and Blood and Marrow Transplantation, Department of Internal…”
Get full text

Capturing daily assessments and home treatment of congenital hemophilia with inhibitors: design, disposition, and implications of the Dosing Observational Study in Hemophilia (DOSE) by Young, Guy, Solem, Caitlyn T, Hoffman, Kate, Kabawat, Jenna, Pickard, A Simon, Gut, Robert Z, Cooper, David L

“…The daily recordings of treatment by patients with congenital hemophilia with inhibitors and their caregivers were assessed as part of the Dosing Observational…”
Get full text